| Literature DB >> 27500412 |
Alan G Hendrick1, Ilka Müller2, Henriëtte Willems1, Philip M Leonard2, Steve Irving3, Richard Davenport1, Takashi Ito4, Jenny Reeves1, Susanne Wright1, Vivienne Allen2, Stephen Wilkinson2, Helen Heffron1, Richard Bazin3, Jennifer Turney2, Philip J Mitchell1.
Abstract
Fatty acid binding protein 6 (FABP6) is a potential drug discovery target, which, if inhibited, may have a therapeutic benefit for the treatment of diabetes. Currently, there are no published inhibitors of FABP6, and with the target believed to be amenable to fragment-based drug discovery, a structurally enabled program was initiated. This program successfully identified fragment hits using the surface plasmon resonance (SPR) platform. Several hits were validated with SAR and were found to be displaced by the natural ligand taurocholate. We report the first crystal structure of human FABP6 in the unbound form, in complex with cholate, and with one of the key fragments.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27500412 DOI: 10.1021/acs.jmedchem.6b00869
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446